Bria-OTS™ (Bria-BRES™)
Metastatic Breast Cancer
Key Facts
Indication
Metastatic Breast Cancer
Phase
Phase 1/2
Status
Active, Recruiting
Company
About BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotech focused on developing targeted cellular immunotherapies to transform cancer care. Its core strategy is advancing Bria-IMT™, a Fast Track-designated candidate in a pivotal Phase 3 study for metastatic breast cancer, while expanding its pipeline through the innovative Bria-OTS™ platform, which enables personalized, off-the-shelf treatments. The company has demonstrated promising clinical data, including extended survival in heavily pre-treated patients, and is backed by collaborations with the National Cancer Institute.
View full company profileTherapeutic Areas
Other Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ZetaMAST (Zeta-MBC-005) | Zetagen Therapeutics | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Vectorized-VX-765 | Atlanthera | Research |
| AURORA 2 Project Collaboration | Seqalis | Phase 2 |
| BPI-1178 (Eciruciclib) | Beta Pharma | Phase 3 |
| Herzuma® | Celltrion | Marketed |
| Eftilagimod alfa (efti) | Immutep | Phase IIb |
| (Z)-endoxifen | Atossa Therapeutics | Phase 1/2 |
| Bria-IMT™ + CPI | BriaCell Therapeutics | Phase 3 |